Existing IBD treatment intervention drugs also include new strategies, such as monoclonal antibodies, which block pro-inflammatory cytokines (tumor necrosis factor-α (TNF-α)), sphingosine 1-phosphate inhibitors, and the JAK kinase inhibitors [5]. Here, TNF is linked to inflammatory bowel disease.